谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.

Katia Cannita,Stefania Paradisi,Valentina Cocciolone,Alberto Bafile,Lucia Rinaldi,Azzurra Irelli,Paola Lanfiuti Baldi,Luigi Zugaro,Rosa Manetta,Edoardo Alesse,Enrico Ricevuto,Corrado Ficorella

CANCER MEDICINE（2016）

引用 6|浏览26
暂无评分
关键词
Bevacizumab,metastatic breast cancer,new schedule,paclitaxel,real life
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要